Cargando…
Machine learning and synthetic outcome estimation for individualised antimicrobial cessation
The decision on when it is appropriate to stop antimicrobial treatment in an individual patient is complex and under-researched. Ceasing too early can drive treatment failure, while excessive treatment risks adverse events. Under- and over-treatment can promote the development of antimicrobial resis...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719971/ https://www.ncbi.nlm.nih.gov/pubmed/36479189 http://dx.doi.org/10.3389/fdgth.2022.997219 |
_version_ | 1784843446834429952 |
---|---|
author | Bolton, William J. Rawson, Timothy M. Hernandez, Bernard Wilson, Richard Antcliffe, David Georgiou, Pantelis Holmes, Alison H. |
author_facet | Bolton, William J. Rawson, Timothy M. Hernandez, Bernard Wilson, Richard Antcliffe, David Georgiou, Pantelis Holmes, Alison H. |
author_sort | Bolton, William J. |
collection | PubMed |
description | The decision on when it is appropriate to stop antimicrobial treatment in an individual patient is complex and under-researched. Ceasing too early can drive treatment failure, while excessive treatment risks adverse events. Under- and over-treatment can promote the development of antimicrobial resistance (AMR). We extracted routinely collected electronic health record data from the MIMIC-IV database for 18,988 patients (22,845 unique stays) who received intravenous antibiotic treatment during an intensive care unit (ICU) admission. A model was developed that utilises a recurrent neural network autoencoder and a synthetic control-based approach to estimate patients’ ICU length of stay (LOS) and mortality outcomes for any given day, under the alternative scenarios of if they were to stop vs. continue antibiotic treatment. Control days where our model should reproduce labels demonstrated minimal difference for both stopping and continuing scenarios indicating estimations are reliable (LOS results of 0.24 and 0.42 days mean delta, 1.93 and 3.76 root mean squared error, respectively). Meanwhile, impact days where we assess the potential effect of the unobserved scenario showed that stopping antibiotic therapy earlier had a statistically significant shorter LOS (mean reduction 2.71 days, [Formula: see text]-value <0.01). No impact on mortality was observed. In summary, we have developed a model to reliably estimate patient outcomes under the contrasting scenarios of stopping or continuing antibiotic treatment. Retrospective results are in line with previous clinical studies that demonstrate shorter antibiotic treatment durations are often non-inferior. With additional development into a clinical decision support system, this could be used to support individualised antimicrobial cessation decision-making, reduce the excessive use of antibiotics, and address the problem of AMR. |
format | Online Article Text |
id | pubmed-9719971 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97199712022-12-06 Machine learning and synthetic outcome estimation for individualised antimicrobial cessation Bolton, William J. Rawson, Timothy M. Hernandez, Bernard Wilson, Richard Antcliffe, David Georgiou, Pantelis Holmes, Alison H. Front Digit Health Digital Health The decision on when it is appropriate to stop antimicrobial treatment in an individual patient is complex and under-researched. Ceasing too early can drive treatment failure, while excessive treatment risks adverse events. Under- and over-treatment can promote the development of antimicrobial resistance (AMR). We extracted routinely collected electronic health record data from the MIMIC-IV database for 18,988 patients (22,845 unique stays) who received intravenous antibiotic treatment during an intensive care unit (ICU) admission. A model was developed that utilises a recurrent neural network autoencoder and a synthetic control-based approach to estimate patients’ ICU length of stay (LOS) and mortality outcomes for any given day, under the alternative scenarios of if they were to stop vs. continue antibiotic treatment. Control days where our model should reproduce labels demonstrated minimal difference for both stopping and continuing scenarios indicating estimations are reliable (LOS results of 0.24 and 0.42 days mean delta, 1.93 and 3.76 root mean squared error, respectively). Meanwhile, impact days where we assess the potential effect of the unobserved scenario showed that stopping antibiotic therapy earlier had a statistically significant shorter LOS (mean reduction 2.71 days, [Formula: see text]-value <0.01). No impact on mortality was observed. In summary, we have developed a model to reliably estimate patient outcomes under the contrasting scenarios of stopping or continuing antibiotic treatment. Retrospective results are in line with previous clinical studies that demonstrate shorter antibiotic treatment durations are often non-inferior. With additional development into a clinical decision support system, this could be used to support individualised antimicrobial cessation decision-making, reduce the excessive use of antibiotics, and address the problem of AMR. Frontiers Media S.A. 2022-11-21 /pmc/articles/PMC9719971/ /pubmed/36479189 http://dx.doi.org/10.3389/fdgth.2022.997219 Text en © 2022 Bolton, Rawson, Hernandez, Wilson, Antcliffe, Georgiou and Holmes. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Digital Health Bolton, William J. Rawson, Timothy M. Hernandez, Bernard Wilson, Richard Antcliffe, David Georgiou, Pantelis Holmes, Alison H. Machine learning and synthetic outcome estimation for individualised antimicrobial cessation |
title | Machine learning and synthetic outcome estimation for individualised antimicrobial cessation |
title_full | Machine learning and synthetic outcome estimation for individualised antimicrobial cessation |
title_fullStr | Machine learning and synthetic outcome estimation for individualised antimicrobial cessation |
title_full_unstemmed | Machine learning and synthetic outcome estimation for individualised antimicrobial cessation |
title_short | Machine learning and synthetic outcome estimation for individualised antimicrobial cessation |
title_sort | machine learning and synthetic outcome estimation for individualised antimicrobial cessation |
topic | Digital Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719971/ https://www.ncbi.nlm.nih.gov/pubmed/36479189 http://dx.doi.org/10.3389/fdgth.2022.997219 |
work_keys_str_mv | AT boltonwilliamj machinelearningandsyntheticoutcomeestimationforindividualisedantimicrobialcessation AT rawsontimothym machinelearningandsyntheticoutcomeestimationforindividualisedantimicrobialcessation AT hernandezbernard machinelearningandsyntheticoutcomeestimationforindividualisedantimicrobialcessation AT wilsonrichard machinelearningandsyntheticoutcomeestimationforindividualisedantimicrobialcessation AT antcliffedavid machinelearningandsyntheticoutcomeestimationforindividualisedantimicrobialcessation AT georgioupantelis machinelearningandsyntheticoutcomeestimationforindividualisedantimicrobialcessation AT holmesalisonh machinelearningandsyntheticoutcomeestimationforindividualisedantimicrobialcessation |